{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:12:27Z","timestamp":1763467947529},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s11934-009-0072-1","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T05:25:12Z","timestamp":1257398712000},"page":"453-459","source":"Crossref","is-referenced-by-count":6,"title":["Testosterone therapy and prostate carcinoma"],"prefix":"10.1007","volume":"10","author":[{"given":"Ernani Luis","family":"Rhoden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcio Augusto","family":"Averbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,6]]},"reference":[{"key":"72_CR1","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/j.1743-6109.2008.00925.x","volume":"5","author":"E.L. Rhoden","year":"2008","unstructured":"Rhoden EL, Averbeck MA, Teloken PE: Androgen replacement in men undergoing treatment for prostate carcinoma. J Sex Med 2008, 5:2202\u20132208.","journal-title":"J Sex Med"},{"key":"72_CR2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.ju.0000143942.55896.64","volume":"173","author":"P.K. Agarwal","year":"2005","unstructured":"Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate carcinoma. J Urol 2005, 173:533.","journal-title":"J Urol"},{"key":"72_CR3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1743-6109.2007.00531.x","volume":"44Pt1","author":"M. Maggi","year":"2007","unstructured":"Maggi M, Schulman C, Quinton R, et al.: The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med 2007, 4(4 Pt 1):1056\u20131069.","journal-title":"J Sex Med"},{"key":"72_CR4","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1743-6109.2007.00545.x","volume":"4","author":"S. Garos","year":"2007","unstructured":"Garos S, Kluck A, Aronoff D: Prostate carcinoma patients and their partners: differences in satisfaction indices and psychological variables. J Sex Med 2007, 4:1394\u20131403.","journal-title":"J Sex Med"},{"key":"72_CR5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1743-6109.2007.00547.x","volume":"4","author":"C.J. Nelson","year":"2007","unstructured":"Nelson CJ, Choi JM, Mulhall JP, Roth AJ: Determinants of sexual satisfaction in men with prostate carcinoma. J Sex Med 2007, 4:1422\u20131427.","journal-title":"J Sex Med"},{"key":"72_CR6","first-page":"293","volume":"1","author":"C. Huggins","year":"1941","unstructured":"Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293.","journal-title":"Cancer Res"},{"key":"72_CR7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ijc.11572","volume":"108","author":"P. Stattin","year":"2004","unstructured":"Stattin P, Lumme S, Tenkanen L, et al.: High levels of circulating testosterone are not associated with increased prostate carcinoma risk: a pooled prospective study. Int J Cancer 2004, 108:418.","journal-title":"Int J Cancer"},{"key":"72_CR8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/pros.20588","volume":"67","author":"S. Wiren","year":"2007","unstructured":"Wiren S, Stocks T, Rinaldi S, et al.: Androgens and prostate carcinoma risk: a prospective study. Prostate 2007, 67:1230.","journal-title":"Prostate"},{"key":"72_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1055-9965.EPI-05-0633","volume":"15","author":"G. Severi","year":"2006","unstructured":"Severi G, Morris HA, MacInnis RJ, et al.: Circulating steroid hormones and the risk of prostate carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15:86\u201391.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"72_CR10","first-page":"967","volume":"6","author":"L.J. Vatten","year":"1997","unstructured":"Vatten LJ, Ursin G, Ross RK, et al.: Androgens in serum and the risk of prostate carcinoma: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 1997, 6:967\u2013969.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"72_CR11","first-page":"1410","volume":"12","author":"C. Chen","year":"2003","unstructured":"Chen C, Weiss NS, Stanczyk FZ, et al.: Endogenous sex hormones and prostate carcinoma risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003, 12:1410\u20131416.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"72_CR12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","volume":"100","author":"A.W. Roddam","year":"2008","unstructured":"Roddam AW, Allen NE, Appleby P, et al.: Endogenous sex hormones and prostate carcinoma: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008, 100:170\u2013183.","journal-title":"J Natl Cancer Inst"},{"key":"72_CR13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jnci\/88.16.1118","volume":"88","author":"P. Gann","year":"1996","unstructured":"Gann P, Hennekens C, Ma J, et al.: Prospective study of sex hormone levels and risk of prostate carcinoma. J Natl Cancer Inst 1996, 88:1118\u20131126.","journal-title":"J Natl Cancer Inst"},{"key":"72_CR14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1055-9965.EPI-04-0715","volume":"14","author":"J.K. Parsons","year":"2005","unstructured":"Parsons JK, Carter HB, Platz EA, et al.: Serum testosterone and the risk of prostate carcinoma: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005, 14:2257\u20132260.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"72_CR15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1056\/NEJMra022251","volume":"350","author":"E.L. Rhoden","year":"2004","unstructured":"Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482.","journal-title":"N Engl J Med"},{"key":"72_CR16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/01.ju.0000136269.10161.32","volume":"172","author":"J.M. Kaufman","year":"2004","unstructured":"Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate carcinoma in hypogonadal men. J Urol 2004, 172:920.","journal-title":"J Urol"},{"key":"72_CR17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1210\/jc.2005-2847","volume":"91","author":"S. Bhasin","year":"2006","unstructured":"Bhasin S, Cunningham GR, Hayes FJ, et al.: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:1995.","journal-title":"J Clin Endocrinol Metab"},{"key":"72_CR18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0022-5347(17)38409-4","volume":"145","author":"W.M. Weerden van","year":"1991","unstructured":"van Weerden WM, van Steenbrugge GJ, van Kreuningen A, et al.: Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice. J Urol 1991, 145:631.","journal-title":"J Urol"},{"key":"72_CR19","first-page":"473","volume":"17","author":"O.H. Pearson","year":"1957","unstructured":"Pearson OH: Discussion of Dr. Huggins\u2019 paper: control of cancers of man by endocrinological methods. Cancer Res 1957, 17:473.","journal-title":"Cancer Res"},{"key":"72_CR20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(17)54531-0","volume":"126","author":"J.E. Fowler Jr","year":"1981","unstructured":"Fowler JE Jr, Whitmore WF Jr: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981, 126:372.","journal-title":"J Urol"},{"key":"72_CR21","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/1097-0142(196711)20:11<1871::AID-CNCR2820201112>3.0.CO;2-D","volume":"20","author":"G.R. Prout Jr","year":"1967","unstructured":"Prout GR Jr, Brewer WR: Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967, 20:1871.","journal-title":"Cancer"},{"key":"72_CR22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.eururo.2006.06.034","volume":"50","author":"A. Morgentaler","year":"2006","unstructured":"Morgentaler A: Testosterone and prostate carcinoma: an historical perspective on a modern myth. Eur Urol 2006, 50:935.","journal-title":"Eur Urol"},{"key":"72_CR23","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","volume":"296","author":"L.S. Marks","year":"2006","unstructured":"Marks LS, Mazer NA, Mostaghel E, et al.: Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006, 296:2351.","journal-title":"JAMA"},{"key":"72_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1743-6109.2005.20233.x","volume":"2","author":"A.I. El-Sakka","year":"2005","unstructured":"El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA: Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med 2005, 2:235\u2013240.","journal-title":"J Sex Med"},{"key":"72_CR25","doi-asserted-by":"crossref","first-page":"E1172","DOI":"10.1152\/ajpendo.2001.281.6.E1172","volume":"281","author":"S. Bhasin","year":"2001","unstructured":"Bhasin S, Woodhouse L, Casaburi R, et al.: Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001, 281:E1172.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"72_CR26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-5347(01)63944-2","volume":"159","author":"C.S. Cooper","year":"1998","unstructured":"Cooper CS, Perry PJ, Sparks AE, et al.: Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998, 159:441.","journal-title":"J Urol"},{"key":"72_CR27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0022-5347(01)64881-X","volume":"157","author":"K.R. Loughlin","year":"1997","unstructured":"Loughlin KR, Richie JP: Prostate carcinoma after exogenous testosterone treatment for impotence. J Urol 1997, 157:1845.","journal-title":"J Urol"},{"key":"72_CR28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-4295(98)00348-3","volume":"53","author":"M.J. Curran","year":"1999","unstructured":"Curran MJ, Bihrle W 3rd: Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999, 53:423.","journal-title":"Urology"},{"key":"72_CR29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0090-4295(01)01235-3","volume":"58","author":"G.J. Bubley","year":"2001","unstructured":"Bubley GJ: Is the flare phenomenon clinically significant? Urology 2001, 58:5.","journal-title":"Urology"},{"key":"72_CR30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1056\/NEJM198908173210701","volume":"321","author":"J.M. Kuhn","year":"1989","unstructured":"Kuhn JM, Billebaud T, Navratil H, et al.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989, 321:413.","journal-title":"N Engl J Med"},{"key":"72_CR31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0022-5347(05)66353-7","volume":"165","author":"K. Tomera","year":"2001","unstructured":"Tomera K, Gleason D, Gittelman M, et al.: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate carcinoma. J Urol 2001, 165:1585.","journal-title":"J Urol"},{"key":"72_CR32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1743-6109.2009.01161.x","volume":"4","author":"M. Khera","year":"2009","unstructured":"Khera M, Grober ED, Najari B, et al.: Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009, 4:1165\u20131170.","journal-title":"J Sex Med"},{"key":"72_CR33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22438","volume":"109","author":"M.F. Sarosdy","year":"2007","unstructured":"Sarosdy MF: Testosterone replacement for hypogonadism after treatment of early prostate carcinoma with brachytherapy. Cancer 2007, 109:536.","journal-title":"Cancer"},{"key":"72_CR34","doi-asserted-by":"crossref","unstructured":"Morales A, Black AM, Emerson LE: Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate carcinoma: preliminary observations. BJU Int 2008, doi:10.1111\/j.1464-410X.2008.07882.x.","DOI":"10.1111\/j.1464-410X.2008.07882.x"},{"key":"72_CR35","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1996.03540230054035","volume":"276","author":"A. Morgentaler","year":"1996","unstructured":"Morgentaler A, Bruning CO 3rd, DeWolf WC: Occult prostate carcinoma in men with low serum testosterone levels. JAMA 1996, 276:1904.","journal-title":"JAMA"},{"key":"72_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/ijir.2008.31","volume":"21","author":"R. Shabsigh","year":"2009","unstructured":"Shabsigh R, Crawford ED, Nehra A, Slawin KM: Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009, 21:9\u201323.","journal-title":"Int J Impot Res"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-009-0072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-009-0072-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-009-0072-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:52:08Z","timestamp":1559436728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-009-0072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s11934-009-0072-1","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}